… the clinical benefit of nusinersen in subgroups of patients with SMA. Nusinersen represents
the first … En esta revisión ejemplificamos el beneficio clínico de Nusinersen en subgrupos de …

… Areas covered: This article reviews the results of the published open label nusinersen … yet
unpublished nusinersen–sham controlled trials, as well as the presymptomatic nusinersen trial …

… and safety of nusinersen (Spinraza) in the treatment of spinal muscular atrophy (SMA). Data
… using the terms nusinersen, ISIS-SMN (Rx), and spinal muscular atrophy. Manufacturer …

… Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease
characterized by progressive weakness and atrophy of the … Nusinersen is a synthetic antisense …

… , nusinersen has to be applied every 4 months into the cerebrospinal fluid. In initial studies,
repeated lumbar … Considering that the treatment with nusinersen may become an integral part …

… nusinersen improves motor function in children with later-onset SMA. Spinal muscular
atrophy (SMA) is a neuromuscular disorder characterized by progressive muscular atrophy and …

… It has been developed for the treatment of spinal muscular atrophy (… Spinal muscular atrophy
(SMA) is an autosomal recessive neuromuscular disorder that is characterized by atrophy …

… Spinal muscular atrophy (SMA) is an autosomal recessively inherited disease, which is
characterized by progressive loss of motor neurons, leading to muscle atrophy … where nusinersen …

… Nusinersen (Spinraza) is a recently approved drug for treating spinal muscular atrophy.
Approval of nusinersen may signal new opportunities for using antisense oligonucleotides as …

… We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety
trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-…